Biocept
Biocept is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Biocept.
Biocept is a company.
Key people at Biocept.
Key people at Biocept.
Biocept, Inc. is a molecular oncology diagnostics company that develops and commercializes proprietary liquid biopsy assays, including its patented Target Selector™ platform, to detect circulating tumor cells (CTCs), cell-free tumor DNA (ctDNA), and cell-free tumor RNA (ctRNA) from blood or cerebrospinal fluid (CSF) samples.[1][2][3] These assays serve medical oncologists, neuro-oncologists, and biopharmaceutical companies by providing actionable biomarker information to personalize cancer treatment, monitor disease progression, and support clinical trials for solid tumors like breast, lung, gastric, colorectal, prostate, and melanoma.[1][2][3][4] The company solves the problem of invasive tissue biopsies by enabling non-invasive testing that identifies mutations and therapeutic options, improving patient outcomes in metastatic cancers where early detection boosts survival rates.[1][4] During the COVID-19 pandemic, Biocept pivoted to RT-PCR testing, processing over 380,000 samples and scaling capacity to 5,000 tests per day, which fueled expansion while maintaining its core cancer focus.[2][6]
Biocept emerged as an early-stage molecular diagnostics firm focused on cancer, with roots in developing CTC and ctDNA/ctRNA assays performed in its CLIA-accredited lab.[1][3] Key leadership includes Michael W. Nall as President and CEO, who in 2018 highlighted progress like expanding to 15 CLIA-certified biomarker tests and securing 25 global patents for Target Selector™.[3] Veena Singh, M.D., Senior VP and Senior Medical Director, led studies validating the platform for metastatic breast cancer hormonal status.[4] The idea stemmed from advancing liquid biopsy to replace tissue sampling, launching initial assays for breast, lung, gastric, colorectal, and prostate cancers, with pivotal moments including partnerships (e.g., Thermo Fisher), new health plan contracts, and CNSide™ CSF assay for brain metastases.[1][3][6] Early traction built through thousands of tests, industry guidelines endorsing liquid biopsy for lung cancer, and a COVID-19 pivot in 2020 that processed 380,000+ samples, enabling facility expansion in San Diego.[3][6]
Biocept rides the liquid biopsy trend in precision oncology, where non-invasive tests enable personalized therapies amid rising FDA approvals for molecularly targeted drugs and companion diagnostics.[1][3] Timing aligns with industry guidelines (e.g., for lung cancer) and growing demand for monitoring metastatic disease, where early detection via CTCs/ctDNA improves survival per American Cancer Society data.[1][4] Market forces like increasing cancer prevalence, biopharma focus on next-gen therapies (e.g., from AstraZeneca, Pfizer), and post-COVID molecular testing infrastructure favor Biocept's CLIA-validated platform.[1][5][6] It influences the ecosystem by enabling pharma clinical studies, standardizing liquid biopsy as care, and bridging diagnostics with treatments for solid tumors.[1][3]
Biocept's momentum from cancer assays, CNSide™ launch, and COVID scalability positions it for growth in personalized oncology, with plans for more validations in colorectal/prostate tumors and international partnerships.[1][3][6] Trends like expanding targeted therapies, AI-enhanced biomarkers, and global cancer diagnostics (projected market growth through 2030) will shape its path, potentially via pharma deals or tech licensing.[1][5] Its influence may evolve from niche innovator to standard-of-care enabler if it sustains patent expansion and reimbursement wins, directly advancing the mission of actionable insights from simple blood/CSF tests to improve cancer patient lives.[3][4]
